Navigation Links
Biocon Unveils Renal Therapies for Kidney Disorders

India's premier biotechnology firm Biocon Ltd Thursday announced the launch of renal therapy products for treating kidney disorders and reducing// the risk of such disease.

As the leading producer of immuno-suppressants in the subcontinent, the company has set up a nephrology division to market the new products -- Renodapt (Mycophenolate Mofeti), Tacrograf (Tacrolimus), Cyclophil Me (Cyclosporine micro emulsion), Rapacan (Sirolimus) and Erypro (rHuEpo).

"Our renal therapy will enable patients with transplanted kidneys to become immune to any side effects and make them feel compatible with the new organ. Similarly, Erthropoetin (Epo) will increase the hameoglobin level to develop resistance," Bicon chairperson Kiran Mazumdar-Shaw said at a preview of the product.

Prior to the launch, the company has undertaken extensive trials as per the statutory guidelines to demonstrate the safety and efficacy profile of its products. About 300 kidney patients who were administered the drugs responded well to the treatment.

"Our objective is to protect life affected by kidney failures with biotherapeutics and reduce the risk of the disease in future through research and innovative therapies," Shaw said.

Studies have revealed that kidney disease has grown to be a silent epidemic in the 21st century. Every year millions of people across the world are diagnosed with end stage renal disease (ESRD) necessitating kidney treatments.

"The total market size for nephrology products is about Rs.3 billion and is growing by about 20 percent annually. Of these, the market for immuno-suppressants is about Rs.1.25 billion. We are targeting a market share of 20-25 percent in the next three-five years despite aggressive competition from Indian and multinational players in the country," Biocon marketing president Rakesh Bamzai said.

According to "Kidney International", the official journal of the international societ y of nephrology, the incidence of ESRD is likely to be higher in India than in the developed countries, with gloerulonephritis being the most common cause, accounting for one-third of patients, while diabetic nephropathy accounts for about one-fourth of patients.

"In the absence of national registries, no reliable data is available on the incidence and prevalence of ESRD in India. Treatment of ESRD is a low priority for the cash-strapped public hospitals and in the absence of health insurance plans, less than 10 percent of all patients receive any kind of renal replacement therapy," Shaw added.

Source-IANS
'"/>




Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Biocon To Shift Focus On Innovation To Accelerate Growth
4. Kalam Dedicates New Cancer Drug Developed By Biocon
5. Bayer to Market Biocon Insulin in China
6. Biocon Launches Anti-Cancer Drug
7. Biocon to Launch Anti-arthritis Drug
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Study Unveils New Insight To The Madness Of King George III
10. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
11. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles ... minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised ... teen the hospital’s 30th heart transplant recipient. , “He was playing at home, when ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... One of ... changing of the securement tape is painful for her. "This is why the co-inventor ... patients’ heads," she said. , They then created a prototype of the patent-pending AV-AIR, ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology: